UGN-103
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for UGN-103, covering 2026-01-15 to 2026-01-15. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer [Phase 3]